Boryung Pharmaceutical and Kwangdong Pharmaceutical have successfully evaded the composition patent on Celgene’s multiple myeloma treatment Pomalyst (Pomalidomide).

Overcoming the biggest barrier to receive the preferential sales approval, the two South Korean companies can now release the generics early in January 2024, immediately after the original’s product patent expires.

The industry predicts the two companies assertively strengthening the oncology pipeline would be able to even further expand their anticancer treatment line-up with the patent evasion.

On Mar. 1, a pharmaceutical industry source told the Intellectual Property Trial and Appeal Board has approved